Poly(d,l-lactide-co-glycolide)/hydroxyapatite core-shell nanospheres. Part 1: A multifunctional system for controlled drug delivery

Vukomanović, Marija; Škapin, Srečo D.; Jančar, Boštjan; Maksin, T.; Ignjatović, Nenad; Uskoković, Vuk; Uskoković, Dragan

doi:10.1016/j.colsurfb.2010.09.011

Cited by 35 publications

(52 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4c). Additional processing in the centrifugal field of the suspension of nanoparticles of HAp coated with PLGA has previously led to the formation of spherical morphologies [37,38]; accordingly, since we used centrifugal processing too in the processing method reported herein, spherical morphologies were obtained as well.…”

Section: Resultsmentioning

confidence: 96%

Multifunctional hydroxyapatite and poly(d,l-lactide-co-glycolide) nanoparticles for the local delivery of cholecalciferol

Ignjatović

Uskoković

Ajduković

et al. 2013

Materials Science and Engineering: C

Self Cite

View full text Add to dashboard Cite

Cholecalciferol, vitamin D3, plays an important role in bone metabolism by regulating extracellular levels of calcium. Presented here is a study on the effects of the local delivery of cholecalciferol (D3) using nanoparticulate carriers composed of hydroxyapatite (HAp) and poly(D,L-lactide-co-glycolide) (PLGA). Multifunctional nanoparticulate HAp-based powders were prepared for the purpose of: (a) either fast or sustained, local delivery of cholecalciferol, and (b) the secondary, osteoconductive and defect-filling effect of the carrier itself. Two types of HAp-based powders with particles of narrowly dispersed sizes in the nano range were prepared and tested in this study: HAp nanoparticles as direct cholecalciferol delivery agents and HAp nanoparticles coated with cholecalciferol-loaded poly(D,L)-lactide-co-glycolide (HAp/D3/PLGA). Satisfying biocompatibility of particulate systems, when incubated in contact with MC3T3-E1 osteoblastic cells in vitro, was observed for HAp/D3/PLGA and pure HAp. In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro. Artificial defects induced in the osteoporotic bone of the rat mandible were successfully reconstructed following implantation of cholecalciferol-coated HAp nanoparticles as well as those comprising HAp nanoparticles coated with cholecalciferol-loaded PLGA (HAp/D3/PLGA). The greatest levels of enhanced angiogenesis, vascularization, osteogenesis and bone structure differentiation were achieved upon the implementation of HAp/D3/PLGA systems.

show abstract

Section: Resultsmentioning

confidence: 96%

Multifunctional hydroxyapatite and poly(d,l-lactide-co-glycolide) nanoparticles for the local delivery of cholecalciferol

Ignjatović

Uskoković

Ajduković

et al. 2013

Materials Science and Engineering: C

Self Cite

View full text Add to dashboard Cite

show abstract

“…349 An opposite approach, that is, coprecipitation of PLGA and a drug, tigecycline, in the presence of precursor HAP nanoparticles was recently implemented, resulting in HAP/PLGA/drug composite particles. 350 They turn out to be particularly appealing not only because of their biocompatible and biodegradable nature, but because HAP releases hydroxyl groups upon dissolution, whereas PLGA releases acidic products of degradation. In combination, the two components thus balance each other's potentially harmful pH changes.…”

Section: Prospective Applicationsmentioning

confidence: 99%

Nanosized hydroxyapatite and other calcium phosphates: Chemistry of formation and application as drug and gene delivery agents

2010

Self Cite

View full text Add to dashboard Cite

The first part of this review looks at the fundamental properties of hydroxyapatite (HAP), the basic mineral constituent of mammalian hard tissues, including the physicochemical features that govern its formation by precipitation. A special emphasis is placed on the analysis of qualities of different methods of synthesis and of the phase transformations intrinsic to the formation of HAP following precipitation from aqueous solutions. This serves as an introduction to the second part and the main subject of this review, which relates to the discourse regarding the prospects of fabrication of ultrafine, nanosized particles based on calcium phosphate carriers with various therapeutic and/or diagnostic agents coated on and/or encapsulated within the particles. It is said that the particles could be either surface-functionalized with amphiphiles, peptides, proteins, or nucleic acids or injected with therapeutic agents, magnetic ions, or fluorescent molecules. Depending on the additive, they could be subsequently used for a variety of applications, including the controlled delivery and release of therapeutic agents (extracellularly or intracellularly), magnetic resonance imaging and hyperthermia therapy, cell separation, blood detoxification, peptide or oligonucleotide chromatography and ultrasensitive detection of biomolecules, and in vivo and in vitro gene transfection. Calcium phosphate nanoparticles as carriers of therapeutic agents that would enable a controlled drug release to treat a given bone infection and at the same be resorbed in the body so as to regenerate hard tissue lost to disease are emphasized hereby as one of the potentially attractive smart materials for the modern medicine.

show abstract

“…Additionally, it should be underlined that the capacity of each component of the PLGA/HAp core-shells to capture a part of clindamycin independently (as it was shown in Part 1 of this work) [27] and the different release kinetics of the two forms of the drug, i.e., clindamycin-base and clindamycn-2-phosphate (as it was shown in Part 2 of this study) can be brought into relationship. The phosphate form of the drug is mainly physically adsorbed onto the HAp surface and after the emergence of the HAp rods onto the PLGA shells its release starts faster.…”

Section: Degradation Of Plga/hap Vs Drug Releasementioning

confidence: 92%

“…To investigate the degradation process and the drug release PLGA/HAp/clindamycin (PLGA:HAp = 90:10, containing 10% wt of clindamycin) and PLGA/HAp (PLGA:HAp = 90:10) were processed using previously described procedures (explained in more details in Part 1 [27] and Jevtić et al [28,29]). Three parallel series of samples containing 50 mg of PLGA/HAp/clindamycin and PLGA/HAp were dispersed in 10 ml of PBS solution (1 tablet dissolved in 200 ml of water yields 0.137 M sodium chloride, 0.01 M phosphate buffer and 0.0027 M potassium chloride) with Na 3 N (0.2 g/L).…”

Section: In Vitro Release Of the Active Substances From The Plga/hap mentioning

confidence: 99%

Poly(D,L-lactide-co-glycolide)/hydroxyapatite core–shell nanosphere. Part 2: Simultaneous release of a drug and a prodrug (clindamycin and clindamycin phosphate)

Vukomanović¹,

Škapin²,

Poljanšek³

et al. 2011

Colloids and Surfaces B: Biointerfaces

Self Cite

View full text Add to dashboard Cite

Poly(d,l-lactide-co-glycolide)/hydroxyapatite core-shell nanospheres. Part 1: A multifunctional system for controlled drug delivery

Cited by 35 publications

References 50 publications

Multifunctional hydroxyapatite and poly(d,l-lactide-co-glycolide) nanoparticles for the local delivery of cholecalciferol

Multifunctional hydroxyapatite and poly(d,l-lactide-co-glycolide) nanoparticles for the local delivery of cholecalciferol

Nanosized hydroxyapatite and other calcium phosphates: Chemistry of formation and application as drug and gene delivery agents

Poly(D,L-lactide-co-glycolide)/hydroxyapatite core–shell nanosphere. Part 2: Simultaneous release of a drug and a prodrug (clindamycin and clindamycin phosphate)

Contact Info

Product

Resources

About